{
 "name": "育世博-KY",
 "slug": "tw-6976",
 "aliases": [
  "英屬開曼群島商育世博(股)公司",
  "Acepodia",
  "6976"
 ],
 "ticker": "6976",
 "industry": "生技醫療業",
 "website": "https://www.acepodia.com",
 "summary": "育世博-KY（6976）是興櫃的生技醫療類股公司，2017 年成立，2023 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "英屬開曼群島商育世博(股)公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "Acepodia",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2023-08-08",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2017-02-15",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "蕭世嘉",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "蕭世嘉",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 5831271100,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "https://www.acepodia.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：ACE723",
   "value": "不可切除或轉移性肝細胞癌｜第I期、尚未招募｜中國",
   "unit": "",
   "as_of": "2026-10-06",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07861425",
   "note": "NCT07861425；ClinicalTrials.gov最後公開更新 2026-10-06；登錄狀態 NOT_YET_RECRUITING。"
  },
  {
   "claim": "管線：ACE723",
   "value": "不可切除或轉移性肝細胞癌｜FDA已核准IND，可啟動第I期｜美國",
   "unit": "",
   "as_of": "2026-09-04",
   "source": "https://www.acepodia.com/newsroom-detail/Acepodia_ACE723_IND_Clearance_en/",
   "note": "NCT07861425為中國試驗登錄；本筆是美國IND清除，非已在美國收案證據。"
  },
  {
   "claim": "管線：ACE1831",
   "value": "IgG4相關疾病｜第I/II期、招募中｜美國、中國",
   "unit": "",
   "as_of": "2026-10-02",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07061938",
   "note": "NCT07061938；ClinicalTrials.gov最後公開更新 2026-10-02；登錄狀態 RECRUITING。"
  },
  {
   "claim": "管線：ACE1831",
   "value": "復發或難治性CD20陽性B細胞惡性腫瘤｜第I期已完成（2026-03-31）｜美國、香港",
   "unit": "",
   "as_of": "2026-06-30",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT05653271",
   "note": "NCT05653271；ClinicalTrials.gov最後公開更新 2026-06-30；登錄狀態 COMPLETED。"
  },
  {
   "claim": "管線：ACE2016",
   "value": "局部晚期或轉移性EGFR陽性實體腫瘤｜第I期、登錄招募中（2025-07-01更新）｜美國、台灣",
   "unit": "",
   "as_of": "2025-07-01",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06415487",
   "note": "NCT06415487；ClinicalTrials.gov最後公開更新 2025-07-01；登錄狀態 RECRUITING。"
  },
  {
   "claim": "催化劑：ACE2016",
   "value": "NCT06415487主要完成日（登錄估計）｜2026-12-31（公司登錄預估）｜已公告",
   "unit": "",
   "as_of": "2025-07-01",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06415487",
   "note": "NCT06415487；由試驗主辦方登錄的Estimated Primary Completion Date，並非解盲、核准或已完成。"
  },
  {
   "claim": "管線：ACE1702",
   "value": "晚期或轉移性HER2陽性實體腫瘤｜第I期已完成（2024-07-15歷史試驗）｜美國、台灣",
   "unit": "",
   "as_of": "2024-12-05",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT04319757",
   "note": "NCT04319757；ClinicalTrials.gov最後公開更新 2024-12-05；登錄狀態 COMPLETED。"
  },
  {
   "claim": "管線：ACE723",
   "value": "不可切除或轉移性肝細胞癌（HCC）｜TFDA核准執行第I期人體試驗｜台灣",
   "unit": "",
   "as_of": "2026-10-15",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "發言日期115/10/15 16:27:44，6976、序號1；主旨：代重要子公司育世博生物科技股份有限公司公告研發中之ADC新藥ACE723第一期臨床試驗獲台灣TFDA核准執行。不是藥品上市核准。"
  },
  {
   "claim": "授權合作：BsAD2C（最多兩項BsADC項目選擇權）",
   "value": "Biocytogen Pharmaceuticals Co., Ltd.｜全球（獨家許可選擇權）｜2026-01-09",
   "unit": "",
   "as_of": "2026-01-09",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "發言日期115/01/09 19:09:00，6976、序號1；主旨：本公司代重要子公司Acepodia Biotechnologies, Ltd.宣布與百奧賽圖（北京）醫藥科技股份有限公司（Biocytogen）達成選擇權與授權合約，共同開發同類首創雙特異性抗體雙藥物複合體。本公司為應付選擇權費一方，未說已行使；具體財務條款未揭露。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6976.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}